Healthline
July 7, 2025
Share on PinterestA new pilot study suggests that liraglutide, a GLP-1RA prescribed for diabetes and weight management, could help reduce migraine frequency. MementoJpeg/Getty Images An Ozempic-like […]
July 6, 2025
Share on PinterestActor Rob Lowe has teamed up with Eli Lilly to encourage more people to participate in cancer clinical trials. Photography courtesy of Rob Lowe […]
July 4, 2025
Share on PinterestA new study reports that polyphenols in coffee may offer protection against type 2 diabets. pocketlight/Getty Images Researchers say black coffee can help lower […]
July 2, 2025
Share on PinterestCompared to BMI scores, body-fat percentages were a stronger predictor of the 15-year mortality risk of young adults, a new study found. Thana Prasongsin/Getty […]
Medscape
July 3, 2025
TOPLINE: Children with chronic spontaneous urticaria (CSU) had significantly lower serum periostin levels than those without the condition. These levels did not correlate with disease activity, […]
July 3, 2025
Research published last year linking wildfire smoke exposure to increased dementia risk has been retracted by the study’s authors after a single stroke coding error was […]
July 3, 2025
Vaccine access and uptake will be affected by the recent actions of the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP), […]
July 3, 2025
It’s a rite of passage — or probably should be — for adults upon reaching 50 years of age: Getting vaccinated for shingles. Currently, the two-dose […]
FDA
August 22, 2025
Docket Number: FDA-2024-N-5313Issued by: Center for Drug Evaluation and Research This is the list of guidances that CDER is considering for development during calendar year 2025. […]
August 21, 2025
FDA has completed their review of the rationale document titled, “Voriconazole Breakpoints for Aspergillus fumigatus” (FR01, May 2024), submitted by the Clinical and Laboratory Standards Institute […]
August 21, 2025
FDA has completed their review of the rationale document titled, “Piperacillin-Tazobactam Breakpoints for Enterobacterales” (MR14, February 2022), submitted by the Clinical and Laboratory Standards Institute (CLSI) […]
August 21, 2025
FDA has completed their review of the rationale document titled, “Piperacillin-Tazobactam Breakpoints for Pseudomonas aeruginosa” (MR15, January 2024), submitted by the Clinical and Laboratory Standards Institute […]
